Project Grant R01CA308071
Award Date 5/11/26
Completion Date 4/30/31
Dollars Obligated $740K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Pennsylvania $178,893.00 under the Cancer Treatment Research program (CFDA 93.395) as a Project Grant effective September 1, 2025, through August 31, 2030. The award supports Dr. Naomi Haas's initiatives to develop and advance immunotherapy clinical trials in renal cell cancer (RCC) for potential integration into the National Clinical Trials Network (NCTN). As a genitourinary medical oncologist and Renal...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $772,208 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on April 10, 2026, with a completion date of March 31, 2031. The award funds research investigating macrophage-directed strategies to enhance the efficacy of poly (ADP-ribose) polymerase inhibitors (PARPIs) in treating BRCA-associated breast cancer. The project combines preclinical validation...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Harvard College's Office for Sponsored Programs a Project Grant of $604,102 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop innovative three-dimensional (3D) bioprinted vascular cancer models. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, will deliver in vitro human and murine cancer models utilizing microporous embedded printing technology to enable...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput technological tools for tracking the fate of prematurely terminated transcripts in cancer cells. The project, which extends through February 28, 2029, focuses on advancing understanding of alternative polyadenylation (APA) events—RNA processing mechanisms that drive oncogenesis independent of DNA...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...